• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tectonic Therapeutic Joins Russell 3000® Index

    6/30/25 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email

    WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.

    The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, results in automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

    For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

    About Tectonic

    Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.



    Contacts:
    
    Investors:
    Dan Ferry
    LifeSci Advisors
    [email protected]
    (617) 430-7576
    
    Media:
    Kathryn Morris
    The Yates Network
    [email protected]
    (914) 204-6412

    Primary Logo

    Get the next $TECX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    7/21/2025$64.00Buy
    Truist
    6/11/2025$76.00Outperform
    Raymond James
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Tectonic Therapeutic with a new price target

    Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

    7/21/25 8:39:42 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Tectonic Therapeutic with a new price target

    Raymond James resumed coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $76.00

    6/11/25 7:55:49 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Tectonic Therapeutic with a new price target

    Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

    4/21/25 8:39:06 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tectonic Therapeutic to Participate in September Investor Conferences

    WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings   Cantor Global Healthcare Conference Date:September 4, 2025Time:2:10 PM EDTLocation:New York, NYFormat:Fireside ChatPresenters:Daniel Lochner, Chief F

    8/28/25 9:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

    TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")Part B of the TX45 Phase 1b clinical trial in subjects with Group 2 Pulmonary Hypertension in Heart Failure with r

    8/7/25 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Joins Russell 3000® Index

    WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization.

    6/30/25 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Reicin Alise covered exercise/tax liability with 859 shares, decreasing direct ownership by 0.40% to 213,485 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/24/25 4:55:39 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Vitorovic Stefan

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/11/25 4:30:29 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Donenberg Phillip B.

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/11/25 4:30:30 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/11/25 6:12:08 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/9/25 5:38:10 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/7/25 4:21:19 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    SEC Filings

    View All

    SEC Form 8-K filed by Tectonic Therapeutic Inc.

    8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    8/7/25 5:08:54 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tectonic Therapeutic Inc.

    10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    8/7/25 4:04:36 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Tectonic Therapeutic Inc.

    EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    7/16/25 12:15:13 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Financials

    Live finance-specific insights

    View All

    Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

    TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

    1/30/25 6:30:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

    Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

    11/7/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

    TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

    8/14/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

    SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/24 4:05:11 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/24/24 5:12:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care